SavedAdd your journal

Journals / İstanbul Tıp Fakültesi Dergisi / 2007 / Cilt: 70 - Sayı: 2

Cytomegalovirus infection after hematopoietic stem cell transplantation: The change in clinical picture, diagnosis, and treatment modality

Hematopoetik kök hücre nakli ve sitomegalovirüs infeksiyonu: Değişen klinik, tanı ve tedavi

Kalayoğlu Sevgi BEŞIŞIK
Erkan ARPACI
Pages
51–55
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this work, determination of high risk stem cell recipients for CMV infection and prophylactic (from the onset of engraftment until 100 days after transplantation) or preemptive (prevention of CMV disease after detection of CMV infection) treatment are reviewed in the context of important literature on this subject.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Cytomegalovirus (CMV) infection takes an important place as a major cause of morbidity and mortality after hematopoietic stem cell transplantation.
📊
Key Findings & Data:There have been significant advances in understanding the pathogenesis of CMV, early detection of virus by modern laboratory technics, and conformable antiviral treatment.
💡
Conclusion & Impact:In this work, determination of high risk stem cell recipients for CMV infection and prophylactic (from the onset of engraftment until 100 days after transplantation) or preemptive (prevention of CMV disease after detection of CMV infection) treatment are reviewed in the context of important literature on this subject.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Cytomegalovirus (CMV) infection takes an important place as a major cause of morbidity and mortality after hematopoietic stem cell transplantation. There have been significant advances in understanding the pathogenesis of CMV, early detection of virus by modern laboratory technics, and conformable antiviral treatment. In this work, determination of high risk stem cell recipients for CMV infection and prophylactic (from the onset of engraftment until 100 days after transplantation) or preemptive (prevention of CMV disease after detection of CMV infection) treatment are reviewed in the context of important literature on this subject.

Özet

Sitomegalovirus (CMV) enfeksiyonu hematopoetik kök hücre naklinden sonra morbidite ve mortalitenin önemli bir nedeni olarak yer almaktadır. Günümüzde CMV patogenezinin anlaşılması ve gelişen modern laboratuvar teknikleri ile virüsün erken tespiti ve uygun antiviral ile tedavisinde önemli ilerlemeler kaydedilmiştir. CMV infeksiyonu için yüksek riskli kök hücre alıcılarının belirlenmesi ve bunların gansiklovir ile profilaktik olarak (nakilden sonra engrafmandan başlayarak 100.güne kadar) veya preemptif (CMV infeksiyonu tespit edildikten sonra hastalığın gelişmesinin önlenmesi) tedavisi bu yazıda önemli çalışmalar ışığında özetlenmiştir.

🔖

Cite This Article

BEŞIŞIK, K. S., ARPACI, E. (2022). Cytomegalovirus infection after hematopoietic stem cell transplantation: The change in clinical picture, diagnosis, and treatment modality. İstanbul Tıp Fakültesi Dergisi, Cilt: 70 - Sayı: 2, 51–55. https://ajindex.com/articles/552701

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Avery RK, Adal KA, Longworth DL, Bolwell BJ. Asurvey of allogeneic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and pre-emptive therapy pre-emptive therapy. Bone Marrow Transplant 2000; 26:763-7
  2. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: randomized double-blind study. Blood 1996; 88:4063-4071
  3. Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 2004; 103: 2003-2008
  4. Broers AE, van Der Holt R, van Esser JW, Gratama JW, Henzen- Logmans S, Kuenen-Boumeester V, Löwenberg B, and Cornelissen JJ. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMVdisease after allogeneic T-cell-depleted stem cell transplantation. Blood 2000; 95: 2240-2245
  5. Britt W, Alford C: Cytomegalovirus. In: Virology. Philadelphia, Pa: Lippincott Raven; 1996, p. 2493
  6. Einsele H, Ehninger G, Hebart H, Wittkowski KM, Schuler U, Jahn G, Mackes P, Herter M, Klingebiel T, Loffler J, Wagner S, Muller CA. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86:2815-2820
  7. Einsele H, Roosnek E, Rufer N, Sinzger C, Riegler S, Löffler J, Grigoleit U, Moris A, Rammensee HG, Kanz L, Kleihauer A, Frank F, Jahn G, and Hebart H. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002; 99: 3916- 3922
  8. Falk CS, Mach M, Schendel DJ, Weiss EH, Hilgert I, Hahn G. NK cell activity during human cytomegalovirus infection is dominated by US2-11-mediated HLAclass I down-regulation. J Immunol 2002; 169:3257-3266
  9. Gratama JW, van Esser JW, Lamers CH, et al. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 2001;98:1358-1364
  10. Howden BP, Michaelides A, Spelman DW, Spencer A, Schwarer AP, Wesselingh S, Kotsimbos TC. Cytomegalovirus viral load monitoring after allogeneic bone marrow transpl